Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies

Published:2021-06 Issue: Volume:168 Page:105579
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Roskoski Robert

Publisher

Elsevier BV

Subject

Pharmacology

Reference128 articles.

1. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting;Thorpe;Nat. Rev. Cancer,2015

2. Targeting the PI3K pathway in cancer: are we making headway?;Janku;Nat. Rev. Clin. Oncol.,2018

3. Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance;Paddock;J. Lipid Res.,2019

4. The ErbB/HER receptor protein-tyrosine kinases and cancer;Roskoski;Biochem. Biophys. Res. Commun.,2004

5. The ErbB/HER family of protein-tyrosine kinases and cancer;Roskoski;Pharmacol. Res.,2014

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17

2. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer;Cell Death & Disease;2024-07-03

3. Tumor biomarkers for diagnosis, prognosis and targeted therapy;Signal Transduction and Targeted Therapy;2024-05-20

4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update;Pharmacological Research;2024-02

5. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases;Pharmacological Research;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3